TWST vs ZBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TWST Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Twist Bioscience Corporation Common Stock (TWST) driven by superior Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, TWST trades at N/M Forward P/E with -28.8% operating margin (+27.9% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, TWST sits in CONSOLIDATION (19th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | TWST Revenue | ZBIO Revenue | TWST Op. Margin | ZBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | N/A | -277.5% | N/A | TWST |
| FY2019 | $50M | N/A | -200.1% | N/A | TWST |
| FY2020 | $90M | N/A | -155.5% | N/A | TWST |
| FY2021 | $130M | N/A | -115.4% | N/A | TWST |
| FY2022 | $200M | N/A | -115.3% | N/A | TWST |
| FY2023 | $250M | $50M | -88.6% | -74.3% | ZBIO |
| FY2024 | $310M | $10M | -70.6% | -3277.8% | TWST |
| FY2025 | $380M | $10M | -36.2% | -3830.6% | TWST |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TWST | ZBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.4B | $1.9B | Larger Scale | TWST |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +27.9% | -100.0% | Higher Growth | TWST |
| Operating Margin (TTM) Profitability | -28.8% | -2747.5% | Higher Margin | TWST |
| Net Profit Margin Profitability | -28.3% | 0.0% | Higher Margin | ZBIO |
| Return on Equity (ROE) Capital Efficiency | -19.1% | -265.1% | Higher ROE | TWST |
| 52-Week Range Position Momentum | 42% ($23โ$220) | 46% ($14โ$45) | Stronger Trend | ZBIO |
| Beta / 30D Volatility Risk Regime | 3.13ฮฒ ยท 126% Vol | 1.16ฮฒ ยท 59% Vol | Lower Realized Risk | ZBIO |
| Unified Institutional Score Composite Signal | 51.7 / 100 (HOLD) | 49.4 / 100 (HOLD) | Higher Composite | TWST |